Rallybio Corporation Common Stock (RLYB)
Smart-money score is above the middle — price trend score is near the top of its range.
RLYB scores higher than 89% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Rallybio Corporation Common Stock (RLYB) scores 63 out of 100 on the Market Census six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.72× 30-day average
- 52-week range
- 3.67 – 17.57
- Market cap
- $91.29M
- Earnings date
- —
- Volume
- 6,942
- Avg. volume (30d)
- 9,632
- Open
- 17.05
- Previous close
- 16.99
- Day's range (regular session)
- 16.95 – 17.22
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for RLYB
- 5 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for RLYB. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about RLYB right now
Rallybio Corporation Common Stock (RLYB) currently scores 63/100 on the Market Census six-factor composite, at the Above average score level. RLYB is +0.18% on the day and -0.35% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for RLYB leans good, with some weak spots. RLYB's strongest factor is insider trades at 90/100 — a very strong read on insider buying and selling. Insider filings currently lean toward buying on this name — a plain read of public filings, not a signal to follow. The weakest factor is company finances at 29/100 — below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See RLYB in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent RLYB news
Latest headlines that name Rallybio, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to RLYB’s 63, all within 1 point.
Sorted by closeness to RLYB’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.